The Met receptor tyrosine kinase is the prototypic member of a small subfamily of growth factor receptors that when activated induce mitogenic, motogenic, and morphogenic cellular responses. The ...

Activation of the tyrosine kinase Src potentiates NMDA-receptor currents, which is thought to be necessary for induction of hippocampal long-term potentiation. Although the carboxy(C)-terminal ...

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor ...

Receptor tyrosine kinases (RTKs) regulate many critical biological processes such as cell growth, differentiation, and survival through the recruitment of intracellular signaling molecules. The ...

ASCO 2025 showcased breakthroughs in sarcoma treatment, emphasizing precision medicine, immunotherapy, and promising new ...

SciLifeLab and AstraZeneca use cryo-EM to advance biomedicine. A study published in Science Advances reveals the mechanism by which the receptor tyrosine kinase RET can increase neuronal survival ...

The researchers found a total of 2,254 unique phosphorylated tyrosine sites, with 7,758 unique kinase-substrate interactions or 10,194 kinase-substrate phosphorylation sites.

Over the last decade, drug discovery efforts have produced a variety of chemical agents that inhibit the EGFR tyrosine kinase, and several of these agents are currently under clinical development.

AstraZeneca (AZ) has shared positive overall survival (OS) results from a late-stage study of its epidermal growth factor ...

Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor indicated for some breast, lung, ovary, kidney, or other cancers.

Tyrosine kinase inhibitors (TKIs) are emerging as a promising class of therapies for managing neovascular age-related macular degeneration (nAMD), addressing the significant burden associated with ...